Orionis Biosciences and the MD Anderson Cancer Center’s Therapeutics Discovery division said on Tuesday that they have teamed up on a research project to advance drug development through genome-scale mapping of drug-target interactions.
Orionis Biosciences and the MD Anderson Cancer Center’s Therapeutics Discovery division said on Tuesday that they have teamed up on a research project to advance drug development through genome-scale mapping of drug-target interactions.